FDA: Abbott May Need More Humira Studies

The FDA is saying that Abbott Laboratories may need to conduct more research into Humira, claiming that the drug may not present an advance in treatment for patients with inflammatory bowel disease. An advisory panel is set to vote on the drug in August.
Reuters